74 related articles for article (PubMed ID: 10808018)
1. Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703.
De Pas TM; Mandalà M; Curigliano G; Peccatori F
Obstet Gynecol; 2000 Jun; 95(6 Pt 2):1030. PubMed ID: 10808018
[No Abstract] [Full Text] [Related]
2. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
Sessa C; Weigang-Köhler K; Pagani O; Greim G; Mora O; De Pas T; Burgess M; Weimer I; Johnson R
Eur J Cancer; 2002 Dec; 38(18):2388-96. PubMed ID: 12460783
[TBL] [Abstract][Full Text] [Related]
4. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer.
D'Agostino G; del Campo J; Mellado B; Izquierdo MA; Minarik T; Cirri L; Marini L; Perez-Gracia JL; Scambia G
Int J Gynecol Cancer; 2006; 16(1):71-6. PubMed ID: 16445613
[TBL] [Abstract][Full Text] [Related]
5. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
[TBL] [Abstract][Full Text] [Related]
6. Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent.
Ghosh AK; Swanson L
J Org Chem; 2003 Dec; 68(25):9823-6. PubMed ID: 14656116
[TBL] [Abstract][Full Text] [Related]
7. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
[TBL] [Abstract][Full Text] [Related]
8. Three new cryptophycins from Nostoc sp. GSV 224.
Subbaraju GV; Golakoti T; Patterson GM; Moore RE
J Nat Prod; 1997 Mar; 60(3):302-5. PubMed ID: 9090872
[TBL] [Abstract][Full Text] [Related]
9. Interaction of the antitumor compound cryptophycin-52 with tubulin.
Panda D; Ananthnarayan V; Larson G; Shih C; Jordan MA; Wilson L
Biochemistry; 2000 Nov; 39(46):14121-7. PubMed ID: 11087360
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of cryptophycin 52 using the Shi epoxidation.
Hoard DW; Moher ED; Martinelli MJ; Norman BH
Org Lett; 2002 May; 4(10):1813-5. PubMed ID: 12000306
[TBL] [Abstract][Full Text] [Related]
11. "Clicktophycin-52": a bioactive cryptophycin-52 triazole analogue.
Nahrwold M; Bogner T; Eissler S; Verma S; Sewald N
Org Lett; 2010 Mar; 12(5):1064-7. PubMed ID: 20131817
[TBL] [Abstract][Full Text] [Related]
12. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Al-Awar RS; Ray JE; Schultz RM; Andis SL; Kennedy JH; Moore RE; Liang J; Golakoti T; Subbaraju GV; Corbett TH
J Med Chem; 2003 Jul; 46(14):2985-3007. PubMed ID: 12825938
[TBL] [Abstract][Full Text] [Related]
13. Toxic brainstem encephalopathy after artemisinin treatment for breast cancer.
White NJ; Ashley EA; Nosten F
Ann Neurol; 2006 Apr; 59(4):725-6. PubMed ID: 16566014
[No Abstract] [Full Text] [Related]
14. Conformational changes in tubulin upon binding cryptophycin-52 reveal its mechanism of action.
Eren E; Watts NR; Sackett DL; Wingfield PT
J Biol Chem; 2021 Oct; 297(4):101138. PubMed ID: 34461087
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
Boinpally RR; Polin L; Zhou SL; Jasti BR; Wiegand RA; White K; Kushner J; Horwitz JP; Corbett TH; Parchment RE
Cancer Chemother Pharmacol; 2003 Jul; 52(1):25-33. PubMed ID: 12739061
[TBL] [Abstract][Full Text] [Related]
16. Protein-binding patterns of the antitumor antibiotic cryptophycin 52 as measured with a two-phase partitioning system.
Kessel D
J Chromatogr B Biomed Sci Appl; 1999 Nov; 735(1):121-6. PubMed ID: 10630897
[TBL] [Abstract][Full Text] [Related]
17. Tri-chloroacetic acid: a cause of vulvar vestibulitis.
Nunns D; Mandal D
Acta Derm Venereol; 1996 Jul; 76(4):334-5. PubMed ID: 8869703
[No Abstract] [Full Text] [Related]
18. Ifosfamide neurotoxicity: an atypical presentation with psychiatric manifestations.
Kerdudo C; Orbach D; Sarradet JL; Doz F
Pediatr Blood Cancer; 2006 Jul; 47(1):100-2. PubMed ID: 16261598
[TBL] [Abstract][Full Text] [Related]
19. Vulvar vestibulitis and risk factors: a population-based case-control study in Oslo.
Edgardh K; Abdelnoor M
Acta Derm Venereol; 2007; 87(4):350-4. PubMed ID: 17598040
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; Tassi R; Civitelli S; Tanzini G; Lorenzi M; Francini G
Cancer Chemother Pharmacol; 2008 Jan; 61(1):105-11. PubMed ID: 17429632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
